BCM
CLSD

Bayesian Capital Management’s Clearside Biomedical CLSD Stock Holding History

Bayesian Capital Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,033
Closed -$35K – 821
2022
Q1 		$35K Buy
+1,033
New +$30.9K 0.01% 740

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bayesian Capital Management's CLSD Position: Q2 2022 in Review

Bayesian Capital Management sold out of Clearside Biomedical (CLSD) in Q2 2022, closing a stake of 1,033 shares — an estimated $35K sold.

Bayesian Capital Management first reported a position in CLSD in Q1 2022 and held it in 1 quarter. The position peaked at $35K in Q1 2022. 53 funds tracked by Wall St. Rank hold CLSD as of Q2 2022.

  • Bayesian Capital Management reported no remaining Clearside Biomedical position as of Q2 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 1,033 Clearside Biomedical shares in Q2 2022, an estimated $35K.
  • Bayesian Capital Management first reported a position in Clearside Biomedical in Q1 2022 and held it in 1 quarter.
  • Bayesian Capital Management's Clearside Biomedical position peaked at $35K in Q1 2022.
  • 53 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2022.

Based on Bayesian Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.